%20(1).webp)

A message lands in the clinic inbox on a Thursday afternoon. A patient stabilised on lisdexamfetamine is flying out in nine days for a five-week trip, and has just read on a forum that they might need “some kind of licence”. The follow-up slot is fifteen minutes and half of it has gone.
Patient-facing guidance on travelling with medication is easy to find. What is harder to find is the version for the person who has to decide what to issue, what to say and what to record. This guide is for ADHD prescribers: which medicines are controlled, what UK guidance actually says about licences and letters, and where your responsibility ends. For the wider governance of stimulant prescribing, see our guide to the adult ADHD titration protocol.
Start with what you have prescribed, not with the travel dates, because the answer changes the whole conversation. Methylphenidate (in every brand and formulation), lisdexamfetamine and dexamfetamine are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. Atomoxetine and guanfacine are prescription-only medicines but are not controlled drugs.
That distinction is the branch point. A patient on atomoxetine needs no controlled-drug paperwork, although a short covering letter still helps at a border. A patient on a stimulant is in scope from the first tablet, and where a patient carries both, the stimulant governs what they need.
Quantity is the lever you control. The length of the trip is fixed by the patient’s plans.
The rules are split across a few official pages, and it is worth being precise about which says what.
The licensing body is the Home Office Drugs and Firearms Licensing Unit (DFLU). The Home Office guidance on travelling with controlled drugs gives the DFLU contact for questions about leaving the UK with controlled drugs. Where a trip is long or the quantity is borderline, the safest advice is for the patient to check the current requirement with the DFLU directly rather than rely on a summary, including this one.
The practical question is how much medicine will cross the border, not how long the patient will be away. Six weeks away with six weeks’ supply sits comfortably under the usual threshold and needs a letter. A patient who wants to carry four months’ supply “to be safe” on the same six-week trip may push themselves into licence territory for no clinical reason.
For a long trip, the question becomes whether the patient needs to carry everything at once. Supply arranged in stages, a return visit, or prescribing at the destination may keep the quantity carried below three months. Each has its own problems, so discuss them early rather than in the last week. Patients considering a break from treatment should understand how their medication works and what stopping it for a period may mean for them.
Make the arithmetic visible. The Home Office letter guidance for people carrying controlled drugs under the personal import policy says it must be evident from the travel dates and quantities that the person is not carrying more than a three-month supply. Writing your letter so the dates and total quantity can be read together does the same job on the way out.
Build this once as a clinic template. GOV.UK’s guidance on the letter for controlled drugs lists the person’s name, a list of the medicines with doses, strength and frequency, and the prescriber’s signature and professional registration details. Good practice adds the rest a border official is likely to need.
Use the generic name first because brand names differ between markets, and an unfamiliar brand gives an official no way to identify the drug. Where a patient takes more than one of the medicines used for ADHD, list each one separately. Advise the patient to keep the medicine in its original labelled pharmacy packaging, which TravelHealthPro also recommends, and to keep a scan of the letter on their phone. Decanting modified-release capsules into a pill organiser removes the label that links the medicine to the prescription and to the patient.
Assume it will. Where there is time, confirm the quantity, issue the letter and direct the patient to the DFLU if a licence may be needed. Where the trip is days away, work through it in order.
Say this to every patient and record that you did. UK paperwork deals with leaving and re-entering the UK. It gives no right to bring the medicine into another country, where the destination’s own law applies. GOV.UK warns that travellers could be fined or imprisoned if they travel with medicine that is illegal in another country.
Your part is to identify whether the medicine is controlled, check the quantity, issue an accurate and timely letter, advise that destination rules are separate, and document that advice. The patient’s part is to check with the embassy of every country they enter or pass through and to comply with what it requires. You cannot check every country’s rules in a fifteen-minute follow-up, and you are not expected to.
A ten-week trip on a monthly prescribing cycle needs supply issued ahead of the cycle. Plan a single early issue rather than a run of urgent requests from abroad, and make sure the quantity on the letter matches what is dispensed. A mismatch between letter and label is exactly what draws attention at a border.
Where the patient is under a shared care agreement, agree in advance who issues the travel supply and the letter. It should be whoever is prescribing the supply the patient will carry, because the dates and quantities must match. Where a brand has been hard to get, involve the pharmacy early and reissue the letter if a substitution is made.
Splitting a controlled drug between hand and hold luggage is not an option, because GOV.UK requires it in hand luggage. If a patient wants a back-up, give them a second copy of the letter, not a second bag of tablets.
Six points give you a defensible record:
The fifth is the one that matters if something goes wrong at a border. Record the advice, not just the letter. Travel is also a sensible prompt to check that routine physical health monitoring is up to date before a long trip.
No. Neither is a controlled drug in the UK. A short letter listing the medicine is still sensible, and the patient should check the rules of the country they are visiting.
GOV.UK accepts a prescription or a doctor’s letter as proof that a controlled drug is the traveller’s. A repeat slip carries no travel dates, destination or total quantity, though, so a proper letter is much more useful at a border.
A UK prescription cannot normally be dispensed abroad. The patient will usually need to see a doctor locally, so a letter confirming the diagnosis and current regimen, kept as a scan on their phone, is the most useful thing you can give them before they go.
Rules on controlled-drug travel, Home Office processes and destination requirements change. Check the current GOV.UK and DFLU guidance at the time of each patient’s trip, not at the time you last read an article about it, and keep the clinic letter template under review.
Stimulant prescribing, monitoring and the governance around it are covered in Global ADHD Network’s ADHD prescribing and management course. For nurses and pharmacists building prescribing practice, see our guide to ADHD prescribing training.
